ENArticle on our MDL-101 published in LAMA2 Europe
An article regarding our MDL-101 for the treatment of LAMA2-CMD has been published in LAMA2 Europe. This follows the publication of our research in the academic journal Human Gene Therapy.
The article highlights our proprietary technology CRISPR-GNDM® and the therapeutic approach that leverages it, presenting new possibilities for gene therapy in LAMA2-CMD. It also notes that the development of this therapy is steadily progressing and is now in the final stages toward the initiation of clinical trials. Additionally, the article mentions that this research could potentially lead to new treatment options for patients with LAMA2-CMD and their families.
We will continue to advance our research and development using CRISPR-GNDM® for diseases with high unmet medical needs, including LAMA2-CMD.
Article:
An important new step toward a treatment for LAMA2-MD thanks to Modalis
“Important new step toward a treatment for LAMA2-MD thanks to Modalis”
About LAMA2 Europe
LAMA2 Europe is a non-profit organization organized and operated by LAMA2-CMD patient groups in Europe (the Netherlands, Spain, and France). The organization’s mission is to accelerate the development of treatments for LAMA2-CMD and to support patients and their families by providing information related to international research activities and other relevant updates. LAMA2 Europe works in collaboration and solidarity with clinicians, researchers, and members of the biotech industry worldwide who are involved in LAMA2-CMD.